Trial Profile
A PHASE IB/II STUDY OF COBIMETINIB ADMINISTERED AS SINGLE AGENT AND IN COMBINATION WITH VENETOCLAX, WITH OR WITHOUT ATEZOLIZUMAB, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 01 Jan 2023 Results assessing safety and efficacy of cobimetinib alone and in combination with venetoclax with or without atezolizumab in patients with relapsed and refractory multiple myeloma published in the Clinical Lymphoma, Myeloma & Leukemia
- 15 Jun 2021 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 14 Jun 2021 Status changed from active, no longer recruiting to completed.